Professor Shawn Hingtgen, Ph.D. will further his research on pediatric brain cancer patients with funding from the Ian’s Friends Foundation for his joint effort with project lead Scott Floyd, M.D., Ph.D., of Duke University around living tissue brain slices. “Ian’s … Read more
Shawn Hingtgen, Ph.D., has been promoted to full professor in the Division of Pharmacoengineering and Molecular Pharmaceutics (DPMP) at the UNC Eshelman School of Pharmacy. He holds a joint appointment as an assistant professor in the Department of Neurosurgery at … Read more
Today, an estimated 700,000 people in the United States are living with a primary brain tumor. Members of the Shawn Hingtgen Lab at the UNC Eshelman School of Pharmacy are focused on curing the disease, specifically glioblastoma, one of the … Read more
Today, an estimated 700,000 people in the United States are living with a primary brain tumor. Members of the Shawn Hingtgen Lab at the UNC Eshelman School of Pharmacy are focused on curing the disease, specifically glioblastoma, one of the … Read more
Shawn Hingtgen, Ph.D., was awarded the Philip and Ruth Hettleman Prize for Artistic and Scholarly Achievement by Young Faculty by the University of North Carolina at Chapel Hill. Hingtgen is an associate professor at the UNC Eshelman School of Pharmacy … Read more
The latest in a series of laboratory breakthroughs could lead to a more effective way to treat the most common brain cancer in children. Scientists from the UNC Eshelman School of Pharmacy and University of North Carolina Lineberger Comprehensive Cancer … Read more
Shawn Hingtgen, Ph.D., a faculty member who is pioneering a new treatment for cancer using induced neural stem cells to deliver therapeutic agents, has been promoted to the rank of associate professor at the UNC Eshelman School of Pharmacy. Due … Read more
Falcon Therapeutics, a company spun out of Assistant Professor Shawn’s Hingtgen’s work treating brain cancer, is one of the ventures contributing to a rise in the economic value of startups connected with the University of North Carolina at Chapel Hill, … Read more
In a rapid-fire series of breakthroughs in just under a year, researchers at the UNC Eshelman School of Pharmacy have made another stunning advance in the development of an effective glioblastoma treatment for a common and aggressive brain cancer. The … Read more
Researchers at the University of North Carolina at Chapel Hill seeking a better treatment for glioblastoma have discovered that removing a brain tumor causes any cancer left behind to grow 75 percent faster than the original tumor did, which helps … Read more
